Dose-Ranging Phase 2b Study of ABX464 in Moderate to Severe Ulcerative Colitis
Trial details
- Registry ID
- NCT03760003
- Phase
- Phase 2
Drug identity checked against registry records
Also recorded as Obefazimod 25 mg
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Dose-Ranging Phase 2b Study of ABX464 in Moderate to Severe Ulcerative ColitisNCT03760003 | ABVX | Phase 2 | Completed | 2021-04-01Actual |
| No regulatory events match this view.This does not mean no FDA events have occurred. |